Helsinki, Finland
Helsinki, Finland

Time filter

Source Type

The scope of this report covers current cancer immunotherapy markets for most common cancers. The market segments included in this report are therapeutic monoclonal antibodies (with special focus on checkpoint inhibitors), synthetic interleukins, interferons, and colony-stimulating factors; small kinase inhibitors of cancer-related targets; protective and therapeutic cancer vaccines; and adoptive cell therapies. This report also covers treatments that are in development for late-stage and early-stage oncolytic viruses. Detailed epidemiological information, discussion of incidence and mortality trends, overview of regulatory landscapes, and analysis of market shares for leading products and companies are also included in this report. 1: Introduction - Goals and Objectives - Reasons for Doing This Study - Intended Audience - Scope of The Study - Information Sources for the Technology Assessment - Forecasting Methodology - Geographic Breakdown 3: Overview - Past and Present of Cancer Immunology - What is Cancer? - Treating Cancer - Challenges in Treating Cancer - Cancer and the Immune System - Immunotherapy - Towards Combination Immunotherapy - Focusing on Cell-mediated Adaptive Immunity - Fine Tuning Versus Boosting Cancer Immunity - Early Versus Advanced Stage Cancer Immunotherapy - Personalized Treatment Paradigm - Clinically Significant Types of Cancers - Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology 4: Overview of Cancer Immunotherapy - Immune System and Immunotherapy - Therapeutic Monoclonal Antibodies - Checkpoint Inhibitors - Biological Response Modifiers - Vaccines - Other - Expanded Information on Selected Product Candidates and Recent Regulatory Applications 7: Company Profiles - Abbvie Inc. - Adaptimmune - Aduro Biotech - Advantagene - Advaxis Immunotherapies - Amgen - Argos Therapeutics - Ariad Pharmaceuticals - Arog Pharmaceuticals - Aserta Pharmaceuticals - Astellas - Astrazeneca - Avax Technologies - Bavarian Nordic - Bayer Healthcare - Biovex - Boehringer Ingelheim - Boston Biomedical - Bristol-Myers Squibb - Cell Medica - Celldex Therapeutics - Celgene Corp. - Chugai - Cold Genesys - Daiichi Sankyo Co. - Dendreon - Dnatrix - Eisai - Eli Lilly - F Hoffmann La Roche AG - Genelux - Gilead Sciences Inc. - Glaxosmithkline Plc - Hanmi Pharmaceutical - Heat Biologics - Immune Design - Immunocellular Therapeutics Ltd. - Immunomedics Inc. - Immunovaccine Inc. - Immunovative Therapies - Incyte Ciorp. - Inovio Pharmaceuticals Inc. - Janssen Pharmaceuticals - Kadmon Pharmaceuticals Corp. - Kite Pharmaceuticals Inc. - Kyowa Hakko Kirin Co. Ltd. - Ligand Pharmaceuticals Inc. - Lion Biotechnologies - Lokon Pharmaceuticals AB - Medimmune - Merck & Co. - Merck Kgaa - Merck Serono - Medigene AG - Mirati Therapeutics - Multivir Inc. - Newlink Genetics - Northwest Biotherapeutics - Novartis Pharma Services AG - Oncolys Biopharma Inc. - Oncolytics Biotech Inc. - Oncomed Pharmaceuticals Inc. - Oncos Therapeutics Ltd. - Ono Pharmaceutical Co. - Otsuka Pharmaceutical Co., Ltd. - Pfizer Inc. - Plexxikon Inc. - Portola Pharmaceuticals Inc. - Provectus Biopharmacueticals Inc. - Psioxus Therapeutics Ltd. - Sanofi SA - Seattle Genetics - Shanghai Sunway Biotech Co. Ltd. - Shenzhen Sibiono Gentech - Sillajen Biotherapeutics Inc. - Spectrum Pharmaceuticals - Takara Bio Inc. - Takeda Co. Ltd. - Tapimmune Inc. - Targovax - Teva Pharmaceutical Industries Ltd. - TG Therapeutics Inc. - Tracon Pharmaceuticals Inc. - Transgene - VCN Biosciences - Ventirx - Verastem Inc. - Viralytics Ltd. - Virttu Biologics Ltd - Vyriad - Western Oncolytics Ltd. For more information about this report visit http://www.researchandmarkets.com/research/fpck42/cancer_immunology To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-cancer-immunology-and-oncolytic-virology-technologies-and-markets-report-2017-market-should-reach-965-billion-by-2021-from-730-billion-in-2016-at-a-cagr-of-57---research-and-markets-300458203.html


Grant
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2011-ITN | Award Amount: 3.86M | Year: 2012

ADVance is designed to integrate 8 leading academic centres and 4 private companies under a single umbrella to create an opportunity to train young scientists in adenovirus (AdV) research. Our full partners and industrial partners represent internationally leading academic centres of excellence in key facets of research into the basic biology of AdV and their application as vectors for clinical protocols in cancer, cardiovascular disease and vaccination that is unique as a training opportunity. Our academic and private sector full partners represent a key areas critical to improved understanding of adenovirus biology and development of key underpinning technology for translational AdV research at the highest level and will create a training opportunity of the highest calibre. The training components are further complemented by our associated partners EASCO that will integrate into ADVance a broad interdisciplinary training and dissemination program. This will ensure the very best training in scientific and key non-scientific skills for each recruited ESRs and ERs. We have also recruited Glen Nemerow as a visiting researcher for his depth of understanding and experience in AdV research over many years. ESR will benefit extensively from the complementarity between the host institutes and strength in depth in training for future careers as well as elevated long term research links for host institutes and companies in the longer term. The network research training is based on a group of well defined and highly innovative research projects applying state-of-the-art methodologies. ADVance will allow lasting collaborations between partners, with and extensive plan of inter-partners secondments of ESR/ERs, which will and create a critical mass of focused adenovirus biologists and translationnal scientists and allow our recruited young researchers to start an excellent career in this field


Patent
Oncos Therapeutics | Date: 2016-04-13

The invention relates to oncolytic adenovirus vectors and their uses in cancer therapy. The adenovirus vectors according to the invention have superior safety properties and have effective therapeutic activity. A production method for the inventive adenoviruses is also disclosed. The adenovirus vectors are useful in cancer therapy.


Patent
Oncos Therapeutics | Date: 2014-11-11

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSP in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject.


Patent
Oncos Therapeutics | Date: 2010-02-02

Oncolytic human adenoviral vectors and cells and pharmaceutical compositions including the vectors. Also provided are methods for using the vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, methods of producing an adenoviral vector are provided.


Patent
Oncos Therapeutics | Date: 2012-11-23

The invention relates to oncolytic adenovirus vectors and their uses in cancer therapy. The adenovirus vectors according to the invention have superior safety properties and have effective therapeutic activity. A production method for the inventive adenoviruses is also disclosed. The adenovirus vectors are useful in cancer therapy.


Patent
Oncos Therapeutics | Date: 2015-09-25

The invention relates to oncolytic adenovirus vectors and their uses in cancer therapy. The adenovirus vectors according to the invention have superior safety properties and have effective therapeutic activity. A production method for the inventive adenoviruses is also disclosed. The adenovirus vectors are useful in cancer therapy.


Patent
Oncos Therapeutics | Date: 2011-09-23

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to said vectors for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing CD40L in a cell and increasing tumor specific immune response and apoptosis in a subject, as well to uses of the oncolytic adenoviral vector of the invention for producing CD40L in a cell and increasing tumor specific immune response and apoptosis, while decreasing tumor-associated immunosuppression, in a subject.


The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to said vectors for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing monoclonal anti-CTLA4 antibodies in a cell and increasing tumor specific immune response and apoptosis in a subject, as well as uses of the oncolytic adenoviral vectors for producing monoclonal anti-CTLA4 antibodies in a cell and increasing tumor specific immune response and apoptosis in a subject.


Lifeline Ventures has never ceased to surprise me. There’s their annual benchpress and dead-lifting contest every November to find the world’s strongest investor and founder. Or, I mean, just look at their portfolio: Trash-sorting robotic systems. Ear-plugs that shine light on the surface of your brain to treat seasonal affective disorder. They even backed the Finnish rock band, the Leningrad Cowboys, to make a game and a feature film about a half-Siberian, half-Mexican dog. They’ve also had some serious wins. They were the first investors in Supercell, the Helsinki-based game developer and maker of Clash of Clans, which eventually sold slightly more than half of itself to Softbank and Gung-Ho Entertainment for $1.53 billion. It was a 4,000X return, says Petteri Koponen, who is the firm’s founding partner (pictured above). Now the firm, which is one of the best-connected in all of Finland, is pulling together a second fund. Counterintuitively, it’s smaller than their first fund at roughly $20 million compared to $30 million. “We had a lot of external pressure to go bigger,” Koponen said. “Quite a few people said that they should be room for a growth-stage fund here, which would have meant we could have raised $100 to 150 million. But we just thought that we would actually maximize our impact if went even earlier stage.” The new fund also doesn’t have a standard lifespan of 10 years. It’s indefinite. “Instead, we could hold companies for 20 years or as long as it takes,” said Lifeline’s other founding partner Timo Ahopelto. “We’d never be in a hurry to sell.” It’s all very Finnish — pragmatic, long-term and maybe a little eccentric. Oh, and with this fund, they’re not planning on focusing too much on games, which might be surprising considering the Renaissance that’s happened over the last five years in the local gaming industry with successes like Angry Birds-maker Rovio and Supercell. “We think the chances of category leadership are pretty slim,” Koponen said. “If we discover the right kinds of games company, we would be super happy to invest. But while game companies can be really attractive and I can understand why the money is flowing there, it’s not our cup of tea.” They’re also excited about a few of their more recent investments like Oncos Therapeutics, which works on targeted cancer therapies and Smartly.io, which is a Facebook ads optimization tool.

Loading Oncos Therapeutics collaborators
Loading Oncos Therapeutics collaborators